---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-032800"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:53:26.628012+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Esperion discloses DSE dispute over $300M milestone payments on CLEAR Outcomes data

## Summary
- NEXLETOL reduced MACE-4 by 13%, MACE-3 by 15%, heart attack by 23%, coronary revascularization by 19% vs placebo.
- Company expects to submit FDA/EMA filings in H1 2023 for label inclusion of CV risk reduction.
- Entitled to $200M-$300M milestone from DSE if EU label includes specific risk reduction; DSE disputes eligibility.
- DSE argues primary endpoint MACE-4 reduction was 12.98%, below 20% threshold; company cites 23% MI reduction.
- Company intends to enforce contractual rights; delay in payment could impact capital needs.

## SEC filing metadata
- accession: 0001104659-23-032800
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465923032800/0001104659-23-032800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465923032800/tm239671d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-032800
- JSON: https://secwatch.observer/filing/0001104659-23-032800.json
- Plain text: https://secwatch.observer/filing/0001104659-23-032800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.